Low Serum Albumin Predicts Severe Outcomes in COVID-19 Infection: A Single-Center Retrospective Case-Control Study

被引:19
作者
Acharya, Roshan [1 ,6 ]
Poudel, Dilli [2 ]
Bowers, Riley [3 ]
Patel, Aakash [1 ]
Schultz, Evan [1 ]
Bourgeois, Michael [1 ]
Paswan, Rishi [1 ]
Stockholm, Scott [1 ]
Batten, Macelyn [1 ]
Kafle, Smita [4 ]
Lonial, Kriti [5 ]
Locklear, Irlene [5 ]
机构
[1] Cape Fear Valley Med Ctr, Dept Internal Med, Fayetteville, NC 28304 USA
[2] Indiana Reg Med Ctr, Dept Rheumatol, Indiana, PA 15701 USA
[3] Cape Fear Valley Med Ctr, Dept Pharm, Fayetteville, NC 28304 USA
[4] Fayetteville State Univ, RN BSN Program, Fayetteville, NC 28301 USA
[5] Cape Fear Valley Med Ctr, Dept Pulmonol & Crit Care, Fayetteville, NC 28304 USA
[6] Campbell Univ, Dept Internal Med, Jerry M Wallace Sch Osteopath Med, Cape Fear Valley Hosp, 1638 Owen Dr, Fayetteville, NC 28304 USA
来源
JOURNAL OF CLINICAL MEDICINE RESEARCH-CANADA | 2021年 / 13卷 / 05期
关键词
COVID-19; SARS-CoV-2; Hypoalbuminemia; Serious outcomes; Mortality; Albumin; ARDS; Hypercoagulopathy; CLINICAL-USE; MORTALITY; SEPSIS;
D O I
10.14740/jocmr4507
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Coronavirus disease 2019 (COVID-19) can cause serious complications such as multiorgan failure and death which are difficult to predict. We conducted this retrospective case-control observational study with the hypothesis that low serum albumin at presentation can predict serious outcomes in COVID-19 infection. Methods: We included severe acute respiratory syndrome corona -virus 2 (SARS-CoV-2) reverse transcriptase-polymerase chain reaction (RT-PCR) confirmed, hospitalized patients from March to July 2020 in a tertiary care hospital in the USA. Patients were followed for 21 days for the development of the primary endpoint defined as the composite outcome which included acute encephalopathy, acute kidney injury, the requirement of new renal replacement therapy, acute hypercoagulability, acute circulatory failure, new-onset heart failure, acute cardiac injury, acute arrhythmia, acute respiratory distress syndrome (ARDS), high flow oxygen support, intensive care unit (ICU) stay, mechanical ventilation or death; and the secondary endpoint of death only. Univariate and multivariate logistic regression analyses were performed to study the effect of albumin level and outcomes.Results: The mean age was 56.76 years vs. 55.67 years (P = 0.68) in the normal albumin vs. the low albumin group. We noticed an inverse relationship between serum albumin at presentation and serious outcomes. The low albumin group had a higher composite out-come (93.88% vs. 6.12%, P < 0.05) and higher mortality (13.87% vs. 2.38%, P < 0.05) in comparison to the normal albumin group. The multivariate logistic regression analysis revealed higher odds of having composite outcomes with lower albumin group (odds ratio (OR) 10.88, 95% confidence interval (CI) 4.74 -24.97, P < 0.05). In the subgroup analysis, the multivariate logistic regression analysis revealed higher odds of having composite outcomes with the very low albumin group (OR 7.94, 95% CI 1.70 -37.14, P < 0.05).Conclusions: Low serum albumin on presentation in COVID-19 infection is associated with serious outcomes not limited to mortality. The therapeutic option of albumin infusion should be investigated.
引用
收藏
页码:258 / 267
页数:10
相关论文
共 47 条
[1]   Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review [J].
Adhikari, Sasmita Poudel ;
Meng, Sha ;
Wu, Yu-Ju ;
Mao, Yu-Ping ;
Ye, Rui-Xue ;
Wang, Qing-Zhi ;
Sun, Chang ;
Sylvia, Sean ;
Rozelle, Scott ;
Raat, Hein ;
Zhou, Huan .
INFECTIOUS DISEASES OF POVERTY, 2020, 9 (01)
[2]   Low Albumin Levels Are Associated with Mortality Risk in Hospitalized Patients [J].
Akirov, Amit ;
Masri-Iraqi, Hiba ;
Atamna, Alaa ;
Shimon, Ilan .
AMERICAN JOURNAL OF MEDICINE, 2017, 130 (12) :1465.e11-1465.e19
[3]   Role of albumin in diseases associated with severe systemic inflammation: Pathophysiologic and clinical evidence in sepsis and in decompensated cirrhosis [J].
Artigas, Antonio ;
Wernerman, Jan ;
Arroyo, Vicente ;
Vincent, Jean-Louis ;
Levy, Mitchell .
JOURNAL OF CRITICAL CARE, 2016, 33 :62-70
[4]  
Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI [10.1056/NEJMoa2007764, 10.1056/NEJMc2022236]
[5]   TUMOR NECROSIS FACTOR-ALPHA INHIBITS ALBUMIN GENE-EXPRESSION IN A MURINE MODEL OF CACHEXIA [J].
BRENNER, DA ;
BUCK, M ;
FEITELBERG, SP ;
CHOJKIER, M .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (01) :248-255
[6]   Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study [J].
Campochiaro, Corrado ;
Della-Torre, Emanuel ;
Cavalli, Giulio ;
De Luca, Giacomo ;
Ripa, Marco ;
Boffini, Nicola ;
Tomelleri, Alessandro ;
Baldissera, Elena ;
Rovere-Querini, Patrizia ;
Ruggeri, Annalisa ;
Monti, Giacomo ;
De Cobelli, Francesco ;
Zangrillo, Alberto ;
Tresoldi, Moreno ;
Castagna, Antonella ;
Dagna, Lorenzo ;
Angelillo, Piera ;
Assanelli, Andrea ;
Calvisi, Stefania ;
Canetti, Diana ;
Cariddi, Adriana ;
Ciceri, Fabio ;
Della Torre, Emanuel ;
Farina, Nicola ;
Fazio, Maria ;
Landoni, Giovanni ;
Mancuso, Gaia ;
Marinosci, Alessandro ;
Oltolini, Chiara ;
Sartorelli, Silvia ;
Scarpellini, Paolo ;
Spessot, Marzia .
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 76 :43-49
[7]   Clinical use of albumin [J].
Caraceni, Paolo ;
Tufoni, Manuel ;
Bonavita, Maria Elena .
BLOOD TRANSFUSION, 2013, 11 :S18-S25
[8]  
Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI [10.1056/NEJMoa2019014, 10.1056/NEJMx200021]
[9]  
Centers for Disease Control and Prevention, 2020, COVID Data Tracker
[10]  
Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]